top of page

SF Healthcare Week: The CEO of Ionis talks about over 30 years of developing RNA therapies, and a new chapter as a commercial forward company

  • blonca9
  • Jan 15
  • 1 min read

Brett Monia discusses the approval of TRYNGOLZA and an important data readout this year in severe hypertriglyceridemia. Plus, the potential approval of donidalorsen for hereditary angioedema, how eplontersen is competing in the transthyretin space, and more.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

bottom of page